Iran

Reimbursed Care Access

Iran maintains strict national drug control laws that broadly prohibit recreational and unregulated use of classical psychedelics; however, ketamine is widely used and studied within Iran’s formal medical system as an anesthetic and for perioperative/analgesic indications. There is no publicly available evidence of regulatory approval or routine reimbursement in Iran for licensed psychedelic therapeutics such as esketamine (Spravato) or for approved medical uses of psilocybin/MDMA; other classic psychedelics are effectively prohibited outside of approved research.